This could explain a possible synergistic effect driving carcinogenesis, hence it imperative that BRCA/Lynch carriers are managed and screened for the whole spectrum of cancers associated with BRCA1/2 and Lynch Syndrome. The gene discussed is BRCA1; the disease is Lynch syndrome.